Basic Information
RNALocate ID: | RLID:11001359 |
RNA Symbol: | hsa-miR-139-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-139-5p |
RNA ID: | miRBase:MIMAT0000250 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001594 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:11001358 | Exosome | Plasma | 29323722 |
RLID:11001360 | Microvesicle | Cerebrospinal fluid | 24797360 |
RLID-D:11000044 | Exosome | Blood | |
RLID-D:11000313 | Microvesicle | Blood|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-139-5p | Diffuse large b cell lymphoma | MNDR-E-MI-13088 |
MNDR | hsa-miR-139-5p | Splenic marginal zone lymphoma | MNDR-E-MI-13089 |
MNDR | hsa-miR-139-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-13090 |
MNDR | hsa-miR-139-5p | Oral squamous cell carcinoma | MNDR-E-MI-13091 |
MNDR | hsa-miR-139-5p | Large cell neuroendocrine cancer | MNDR-E-MI-13092 |
MNDR | hsa-miR-139-5p | Follicular lymphoma | MNDR-E-MI-13093 |
MNDR | hsa-miR-139-5p | Medulloblastoma | MNDR-E-MI-13094 |
MNDR | hsa-miR-139-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-13095 |
MNDR | hsa-miR-139-5p | Lymphoma | MNDR-E-MI-13096 |
MNDR | hsa-miR-139-5p | Lymphoma non-hodgkin | MNDR-E-MI-13097 |
MNDR | hsa-miR-139-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-13098 |
MNDR | hsa-miR-139-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-13099 |
MNDR | hsa-miR-139-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-13100 |
MNDR | hsa-miR-139-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-13101 |
MNDR | hsa-miR-139-5p | Her2-receptor positive breast cancer | MNDR-E-MI-13102 |
MNDR | hsa-miR-139-5p | Breast cancer luminal | MNDR-E-MI-13103 |
MNDR | hsa-miR-139-5p | Prostate cancer | MNDR-E-MI-13104 |
MNDR | hsa-miR-139-5p | Gastric cancer | MNDR-E-MI-13105 |
MNDR | hsa-miR-139-5p | Gastric lymphoma | MNDR-E-MI-13106 |
MNDR | hsa-miR-139-5p | Alzheimer disease | MNDR-E-MI-13107 |
MNDR | hsa-miR-139-5p | Intracranial aneurysm | MNDR-E-MI-13108 |
MNDR | hsa-miR-139-5p | Bladder cancer | MNDR-E-MI-13109 |
MNDR | hsa-miR-139-5p | Esophageal carcinoma | MNDR-E-MI-13110 |
MNDR | hsa-miR-139-5p | Dysautonomia familial | MNDR-E-MI-13111 |
MNDR | hsa-miR-139-5p | Head and neck cancer | MNDR-E-MI-13112 |
MNDR | hsa-miR-139-5p | Primary biliary cirrhosis | MNDR-E-MI-13113 |
MNDR | hsa-miR-139-5p | Huntington disease | MNDR-E-MI-13114 |
MNDR | hsa-miR-139-5p | Chorea | MNDR-E-MI-13115 |
MNDR | hsa-miR-139-5p | Cardiovascular disease | MNDR-E-MI-13116 |
MNDR | hsa-miR-139-5p | Carotid stenosis | MNDR-E-MI-13117 |
MNDR | hsa-miR-139-5p | Uterine fibroid | MNDR-E-MI-13118 |
MNDR | hsa-miR-139-5p | Lung cancer | MNDR-E-MI-13119 |
MNDR | hsa-miR-139-5p | Endometrial cancer | MNDR-E-MI-13120 |
MNDR | hsa-miR-139-5p | Down syndrome | MNDR-E-MI-13121 |
MNDR | hsa-miR-139-5p | Parkinson disease | MNDR-E-MI-13122 |
MNDR | hsa-miR-139-5p | Basal-like breast cancer | MNDR-E-MI-13123 |
MNDR | hsa-miR-139-5p | Neuroendocrine neoplasia | MNDR-E-MI-13124 |
MNDR | hsa-miR-139-5p | Pituitary neoplasms | MNDR-E-MI-13125 |
MNDR | hsa-miR-139-5p | Pancreatic cancer | MNDR-E-MI-13126 |
MNDR | hsa-miR-139-5p | Melanoma | MNDR-E-MI-13127 |
MNDR | hsa-miR-139-5p | Rectum adenocarcinoma | MNDR-E-MI-13128 |
MNDR | hsa-miR-139-5p | Nephroblastoma | MNDR-E-MI-13129 |
MNDR | hsa-miR-139-5p | Colon cancer | MNDR-E-MI-13130 |
MNDR | hsa-miR-139-5p | Colon adenocarcinoma | MNDR-E-MI-13131 |
MNDR | hsa-miR-139-5p | Familial ovarian cancer | MNDR-E-MI-13132 |
MNDR | hsa-miR-139-5p | Basal cell carcinoma | MNDR-E-MI-13133 |
MNDR | hsa-miR-139-5p | Prostate adenocarcinoma | MNDR-E-MI-13134 |
MNDR | hsa-miR-139-5p | Carcinoma ductal breast | MNDR-E-MI-13135 |
MNDR | hsa-miR-139-5p | Glioblastoma | MNDR-E-MI-13136 |
MNDR | hsa-miR-139-5p | Astrocytoma | MNDR-E-MI-13137 |
MNDR | hsa-miR-139-5p | Glioma | MNDR-E-MI-13138 |
MNDR | hsa-miR-139-5p | Oligodendroglioma | MNDR-E-MI-13139 |
MNDR | hsa-miR-139-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-13140 |
MNDR | hsa-miR-139-5p | Osteosarcoma | MNDR-E-MI-13141 |
MNDR | hsa-miR-139-5p | Breast carcinoma | MNDR-E-MI-13142 |
MNDR | hsa-miR-139-5p | Middle cerebral artery infarction | MNDR-E-MI-13143 |
MNDR | hsa-miR-139-5p | Uterine cancer | MNDR-E-MI-13144 |
MNDR | hsa-miR-139-5p | Gastric adenocarcinoma | MNDR-E-MI-13145 |
MNDR | hsa-miR-139-5p | Cervical squamous cell carcinoma | MNDR-E-MI-13146 |
MNDR | hsa-miR-139-5p | Pituitary adenoma | MNDR-E-MI-13147 |
MNDR | hsa-miR-139-5p | Lung squamous cell carcinoma | MNDR-E-MI-13148 |
MNDR | hsa-miR-139-5p | Carcinoma lung non-small-cell | MNDR-E-MI-13149 |
MNDR | hsa-miR-139-5p | Lung adenocarcinoma | MNDR-E-MI-13150 |
MNDR | hsa-miR-139-5p | Adrenocortical carcinoma | MNDR-E-MI-13151 |
MNDR | hsa-miR-139-5p | Adrenal cortical carcinoma | MNDR-E-MI-13152 |
MNDR | hsa-miR-139-5p | Thyroid carcinoma | MNDR-E-MI-13153 |
MNDR | hsa-miR-139-5p | Bladder urothelial carcinoma | MNDR-E-MI-13154 |
MNDR | hsa-miR-139-5p | Pancreatic adenocarcinoma | MNDR-E-MI-13155 |
MNDR | hsa-miR-139-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-13156 |
MNDR | hsa-miR-139-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-13157 |
MNDR | hsa-miR-139-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-13158 |
MNDR | hsa-miR-139-5p | Clear cell renal cell carcinoma | MNDR-E-MI-13159 |
MNDR | hsa-miR-139-5p | Allergic rhinitis | MNDR-E-MI-13160 |
MNDR | hsa-miR-139-5p | Large cell carcinoma | MNDR-E-MI-13161 |
MNDR | hsa-miR-139-5p | Cholangiocarcinoma | MNDR-E-MI-13162 |
MNDR | hsa-miR-139-5p | Gallbladder carcinoma | MNDR-E-MI-13163 |
MNDR | hsa-miR-139-5p | Esophageal cancer | MNDR-E-MI-13164 |
MNDR | hsa-miR-139-5p | Liver cirrhosis | MNDR-E-MI-13165 |
MNDR | hsa-miR-139-5p | Lung small cell carcinoma | MNDR-E-MI-13166 |
MNDR | hsa-miR-139-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-13167 |
MNDR | hsa-miR-139-5p | Breast invasive carcinoma | MNDR-E-MI-13168 |
MNDR | hsa-miR-139-5p | Early hepatocellular carcinoma | MNDR-E-MI-13169 |
MNDR | hsa-miR-139-5p | Familiar ovarian carcinoma | MNDR-E-MI-13170 |
MNDR | hsa-miR-139-5p | B-cell lymphoma | MNDR-E-MI-13171 |
MNDR | hsa-miR-139-5p | Rheumatoid arthritis | MNDR-E-MI-13172 |
MNDR | hsa-miR-139-5p | T-cell leukemia | MNDR-E-MI-13173 |
MNDR | hsa-miR-139-5p | Malignant pleural mesothelioma | MNDR-E-MI-13174 |
MNDR | hsa-miR-139-5p | Barrett's adenocarcinoma | MNDR-E-MI-13175 |
MNDR | hsa-miR-139-5p | Chronic myeloid leukemia | MNDR-E-MI-13176 |
MNDR | hsa-miR-139-5p | Hodgkin lymphoma | MNDR-E-MI-13177 |
MNDR | hsa-miR-139-5p | Burkitt lymphoma | MNDR-E-MI-13178 |
MNDR | hsa-miR-139-5p | Neuromyelitis optica | MNDR-E-MI-13179 |
MNDR | hsa-miR-139-5p | Skin cutaneous melanoma | MNDR-E-MI-13180 |
MNDR | hsa-miR-139-5p | Skin melanoma | MNDR-E-MI-13181 |
MNDR | hsa-miR-139-5p | Acute myelogenous leukemia | MNDR-E-MI-13182 |
MNDR | hsa-miR-139-5p | Colorectal cancer | MNDR-E-MI-13183 |
MNDR | hsa-miR-139-5p | Nasopharyngeal carcinoma | MNDR-E-MI-13184 |
MNDR | hsa-miR-139-5p | Ependymoma | MNDR-E-MI-13185 |
MNDR | hsa-miR-139-5p | Cardiomegaly | MNDR-E-MI-13186 |
MNDR | hsa-miR-139-5p | Prostatic neoplasms | MNDR-E-MI-13187 |
MNDR | hsa-miR-139-5p | Sleep deprivation | MNDR-E-MI-13188 |
MNDR | hsa-miR-139-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-13189 |
MNDR | hsa-miR-139-5p | Barrett's carcinogenesis | MNDR-E-MI-13190 |
MNDR | hsa-miR-139-5p | Breast cancer her3+ negative | MNDR-E-MI-13191 |
MNDR | hsa-miR-139-5p | Cardiac fibrosis | MNDR-E-MI-13192 |
MNDR | hsa-miR-139-5p | Duke A | MNDR-E-MI-13193 |
MNDR | hsa-miR-139-5p | Low grade dysplastic nodule | MNDR-E-MI-13194 |
MNDR | hsa-miR-139-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-13195 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ACTC1 | Homo sapiens | RR00037075 |
TOP